​

MacroGenics (MGNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MGNX Stock Forecast

MacroGenics (MGNX) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $9.44, with a high of $32.00 and a low of $2.00. This represents a 207.49% increase from the last price of $3.07.

- $7 $14 $21 $28 $35 High: $32 Avg: $9.44 Low: $2 Last Closed Price: $3.07

MGNX Stock Rating

MacroGenics stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (50.00%), 10 Hold (45.45%), 1 Sell (4.55%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 1 10 11 Strong Sell Sell Hold Buy Strong Buy

MGNX Price Target Upside V Benchmarks

TypeNameUpside
StockMacroGenics207.49%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$3.00
Last Closing Price$3.07$3.07$3.07
Upside/Downside---2.28%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26115--7
Mar, 26115--7
Feb, 26115--7
Jan, 26115--7
Dec, 25115--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 14, 2025Peter LawsonBarclays$3.00$1.5988.68%-2.28%
Mar 25, 2025H.C. Wainwright$2.00$1.7911.73%-34.85%
Aug 07, 2024Stephen WilleyStifel Nicolaus$6.00$3.3877.51%95.44%
Jul 31, 2024Silvan TuerkcanJMP Securities$8.00$5.2552.38%160.59%
Jul 31, 2024Mayank MamtaniB.Riley Financial$5.00$5.25-4.76%62.87%
Jul 29, 2024Peter LawsonBarclays$9.00$5.5562.16%193.16%
May 23, 2024Kaveri PohlmanBTIG$9.00$4.6394.38%193.16%
May 13, 2024Debjit ChattopadhyayH.C. Wainwright$4.00$4.38-8.68%30.29%
May 10, 2024Peter LawsonBarclays$14.00$14.67-4.57%356.03%
May 10, 2024Etzer DaroutBMO Capital$8.00$14.67-45.47%160.59%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 24, 2026CitigroupMarket PerformMarket Performhold
May 14, 2025BarclaysOverweightOverweighthold
Sep 18, 2024JMP SecuritiesMarket PerformMarket Performhold
Sep 18, 2024H.C. WainwrightNeutralNeutralhold
Sep 16, 2024Cowen & Co.HoldHoldhold
Aug 21, 2024H.C. WainwrightNeutralNeutralhold
Aug 15, 2024JMP SecuritiesMarket PerformMarket Performhold
Jul 31, 2024BTIGBuyNeutraldowngrade
Jul 31, 2024JMP SecuritiesOutperformOutperformhold
Jul 31, 2024GuggenheimAccumulateNeutraldowngrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.18$-1.95$-0.15$-1.07$-1.18---
Avg Forecast$-3.25$-2.03$0.43$-1.20$-2.20$-1.87$-2.31$-2.32
High Forecast$-1.59$-0.80$0.49$-1.02$-0.48$-0.55$-1.70$-0.16
Low Forecast$-5.05$-3.38$0.29$-1.40$-3.47$-3.30$-2.92$-5.50
Surprise %-2.15%-3.94%-134.88%-10.83%-46.36%---

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$75.64M$150.02M$57.19M$148.34M$149.50M---
Avg Forecast$83.89M$150.06M$80.88M$159.93M$77.97M$87.38M$76.42M$120.09M
High Forecast$119.63M$226.35M$92.31M$172.05M$131.38M$88.48M$156.83M$246.44M
Low Forecast$50.95M$79.99M$68.52M$144.41M$18.14M$86.27M$21.65M$34.02M
Surprise %-9.83%-0.03%-29.29%-7.25%91.73%---

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-202.12M$-119.76M$-9.06M$-66.97M$-74.62M---
Avg Forecast$-145.85M$-195.63M$49.82M$-74.81M$-176.54M$-164.31M$-143.21M$-143.88M
High Forecast$-116.68M$-156.51M$59.78M$-62.92M$-29.78M$-34.34M$-105.55M$-9.83M
Low Forecast$-175.02M$-234.76M$39.85M$-86.70M$-215.05M$-204.28M$-180.87M$-340.67M
Surprise %38.58%-38.78%-118.18%-10.49%-57.73%---

MGNX Forecast FAQ

Is MacroGenics stock a buy?

MacroGenics stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 10 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that MacroGenics is a favorable investment for most analysts.

What is MacroGenics's price target?

MacroGenics's price target, set by 22 Wall Street analysts, averages $9.44 over the next 12 months. The price target range spans from $2 at the low end to $32 at the high end, suggesting a potential 207.49% change from the previous closing price of $3.07.

How does MacroGenics stock forecast compare to its benchmarks?

MacroGenics's stock forecast shows a 207.49% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MacroGenics over the past three months?

  • April 2026: 14.29% Strong Buy, 14.29% Buy, 71.43% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 14.29% Strong Buy, 14.29% Buy, 71.43% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 14.29% Strong Buy, 14.29% Buy, 71.43% Hold, 0% Sell, 0% Strong Sell.

What is MacroGenics’s EPS forecast?

MacroGenics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.87, marking a 58.47% increase from the reported $-1.18 in 2025. Estimates for the following years are $-2.31 in 2027, and $-2.32 in 2028.

What is MacroGenics’s revenue forecast?

MacroGenics's average annual revenue forecast for its fiscal year ending in December 2026 is $87.38M, reflecting a -41.55% decrease from the reported $149.5M in 2025. The forecast for 2027 is $76.42M, and $120.09M for 2028.

What is MacroGenics’s net income forecast?

MacroGenics's net income forecast for the fiscal year ending in December 2026 stands at $-164M, representing an 120.20% increase from the reported $-74.62M in 2025. Projections indicate $-143M in 2027, and $-144M in 2028.